Dauntless 1's Series B Round

Dauntless 1 raised a round of funding on January 07, 2017. Investors include Sofinnova Ventures.

Dauntless 1 is developing a therapeutic agent, DP1038, for the treatment of endocrine cancers in Dauntless 1. DP1038 will follow a 505(b)(2) pathway to speed development and reduce costs. DP1038 compl…

Articles about Dauntless 1's Series B Round: